REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Tobacco firm Philip Morris seals deal for UK's Vectura with 75% support

Thu, 16th Sep 2021 07:33

* Holders of roughly 75% Vectura shares tender support

* PMI needed 50% backing for deal to go through

* Extends deadline for other holders to tender shares by
Sept. 30
(Adds detail, background)

By Pushkala Aripaka

Sept 16 (Reuters) - Cigarette maker Philip Morris (PMI)
has clinched the roughly 1-billion-pound takeover of
inhaler maker Vectura after winning the backing of about
75% of shareholders in the British company, part of its
expansion beyond tobacco.

Vectura shareholders had until Sept. 15 to decide whether to
support the 165 pence-per-share bid from PMI, which sought to
buy the London-listed asthma drug maker as part of its plan to
go "smoke-free" and switch to healthcare and wellness products.

"We have reached an important milestone in our acquisition
of Vectura and are pleased to have secured over 74% of the
company's shares, in excess of the 50% required to make our
offer unconditional and PMI the majority shareholder," PMI Chief
Executive Jacek Olczak said in a statement on Thursday.

PMI had received the shares from shareholders through a
public tender offer process, and the cigarette maker's offer for
Vectura cannot be withdrawn now.

PMI, which fought off private equity firm Carlyle Group
for the buyout of Vectura, had switched its proposal to a
takeover offer from a so-called scheme of arrangement to raise
its chances.

The switch allowed PMI to require the support of holders of
just over 50% of Vectura shares for the deal to go through.

Philip Morris has received regulatory clearances for the
deal and had won the backing of Vectura's board, but health
groups are questioning the idea of a tobacco company making
money from treating the very illnesses that cigarettes cause.

Olczak said PMI would provide Vectura's scientists with the
resources and expertise to reach a target of at least $1 billion
in net revenue from its "Beyond Nicotine" products by 2025.

The U.S.-based company has also extended the deadline for
the remaining Vectura shareholders to tender their shares to
Sept. 30.

($1 = 0.7234 pounds)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Devika
Syamnath and Emelia Sithole-Matarise)

More News
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
4 Dec 2020 13:05

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Read more
30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Read more
30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

Read more
20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

Read more
19 Nov 2020 20:25

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
15 Sep 2020 17:22

Vectura Revenue Slips But Swings To First Half Profit

Vectura Revenue Slips But Swings To First Half Profit

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
9 Jun 2020 12:04

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

Read more
8 Jun 2020 15:00

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.